| SETX — Senataxin | |
|---|---|
| Symbol | SETX |
| Full Name | Senataxin |
| Chromosome | 9q34.13 |
| NCBI Gene | 23067 |
| Ensembl | ENSG00000112297 |
| OMIM | 604465 |
| UniProt | Q9UH73 |
| Diseases | [Amyotrophic Lateral Sclerosis](/diseases/als) (ALS4), [Ataxia with Oculomotor Apraxia Type 2](/diseases/ataxia-oculomotor-apraxia) |
| Expression | Brain, Spinal cord, Testis, Liver |
Setx Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SETX (Senataxin) is a gene located on chromosome 9q34.13 that encodes a DNA/RNA helicase protein[1]. Mutations in SETX cause a juvenile-onset form of Amyotrophic Lateral Sclerosis known as ALS4, as well as Ataxia with Oculomotor Apraxia Type 2 (AOA2)[2]. The gene is catalogued as NCBI Gene ID 23067.
Senataxin is a large nuclear protein with RNA/DNA helicase activity that plays critical roles in transcription termination, RNA processing, and DNA repair[3]. The protein belongs to the superfamily 1 helicases and is expressed predominantly in neurons, particularly motor neurons[4].
The SETX gene encodes a protein belonging to the superfamily 1 helicases with both ATP-dependent DNA and RNA helicase activity[4:1]. The protein is predominantly nuclear and is expressed in neurons, particularly motor neurons.
Senataxin participates in several critical cellular processes:
The helicase activity of senataxin allows it to:
SETX mutations cause a unique form of juvenile-onset ALS characterized by[2:2][8]:
SETX mutations also cause AOA2, a recessive disorder characterized by[9][10]:
Several pathogenic variants have been identified in SETX:
SETX mutations show population-specific patterns:
SETX mutations cause neurodegeneration through several interconnected mechanisms:
SETX represents a therapeutic target for ALS and related disorders:
Current research on SETX focuses on:
The study of Setx Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Links verified: 2026-03-16
Morey, N.J., et al. (2001). Molecular and Cellular Biology. 2001. ↩︎
Chance, P.F., et al. (1998). Neurology. 1998. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Yüce, O. & West, S.C. (2013). Senataxin, defective in the neurodegenerative disease ataxia with oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage. Journal of Cell Biology. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Suraweera, A., et al. (2009). Journal of Cell Biology. 2009. ↩︎ ↩︎
House, N.C., et al. (2014). Nature Structural & Molecular Biology. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Skariah, S. & Colognato, H. (2017). Molecular pathways linking innate immunity and the central nervous system development. Molecular Neurobiology. 2017. ↩︎ ↩︎ ↩︎
Richard, P., et al. (2013). Current Opinion in Genetics & Development. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Chen, Y.Z., et al. (2004). American Journal of Human Genetics. 2004. ↩︎ ↩︎ ↩︎
Hentati, F., et al. (2014). Neurodegenerative Diseases. 2014. ↩︎ ↩︎ ↩︎
Skariah, S., et al. (2019). Molecular Neurobiology. 2019. ↩︎ ↩︎